{"protocolSection":{"identificationModule":{"nctId":"NCT01397500","orgStudyIdInfo":{"id":"CS/Muenchen 02"},"organization":{"fullName":"Max-Planck-Institute of Psychiatry","class":"OTHER"},"briefTitle":"Hormone Treatment in Growth Hormone and Testosterone Deficient Patients","officialTitle":"Growth Hormone and Gonadotropin Deficiency After Brain Injury (Traumatic Brain Injury, Subarachnoidal Hemorrhage, Ischemic Stroke): the Effects of Hormone Replacement on Cognition, Quality of Life and Body Composition"},"statusModule":{"statusVerifiedDate":"2016-01","overallStatus":"TERMINATED","whyStopped":"Recruitment problems due to change of patient population at site.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-11"},"primaryCompletionDateStruct":{"date":"2015-02","type":"ACTUAL"},"completionDateStruct":{"date":"2015-03","type":"ACTUAL"},"studyFirstSubmitDate":"2011-05-17","studyFirstSubmitQcDate":"2011-07-18","studyFirstPostDateStruct":{"date":"2011-07-19","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-01-08","lastUpdatePostDateStruct":{"date":"2016-01-11","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Max-Planck-Institute of Psychiatry","class":"OTHER"},"collaborators":[{"name":"Schoen Clinic Bad Aibling","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Growth hormone and gonadotropin deficiency after brain injury (traumatic brain injury, ischemic stroke, subarachnoidal hemorrhage): the effects of hormone replacement on cognition, quality of life and body composition Randomized, controlled, 3 arm (group 2: double-blind; groups 1 and 3: open), multi-center, pilot study (Phase II)","detailedDescription":"The aim of the study is to investigate the influence of growth-hormone replacement on cognition, quality of life, body mass index, body composition and reorganization of brain activity of hypopituitary patients in a stable, chronic phase after brain injury compared to control patients and the influence of testosterone replacement in gonadotropin deficient patients compared to placebo treated control patients."},"conditionsModule":{"conditions":["Hormone Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":54,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Genotropin","type":"ACTIVE_COMPARATOR","description":"6 months Genotropin (open treatment)\n\nDaily dose:\n\nMale \\< 45 years: 0,4 mg; ≥ 45 years: 0,2 mg Female \\< 45 years: 0,5 mg; ≥ 45 years: 0,3 mg Starting with half of the dose for the first 4 weeks.","interventionNames":["Drug: Genotropin"]},{"label":"Testosterone undecannoate","type":"ACTIVE_COMPARATOR","description":"18 weeks testosterone undecanoate/placebo (double-blind treatment) 1000 mg/4 ml at baseline and after 6 weeks","interventionNames":["Drug: Testosterone undecannoate"]},{"label":"control group","type":"NO_INTERVENTION","description":"No Intervention."}],"interventions":[{"type":"DRUG","name":"Genotropin","description":"Genotropin administered sc once a day by patient or caregiver.","armGroupLabels":["Genotropin"],"otherNames":["GH"]},{"type":"DRUG","name":"Testosterone undecannoate","description":"Testosterone undecannoate administered twice (6 week Interval) im by investigator.","armGroupLabels":["Testosterone undecannoate"],"otherNames":["Testo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Quality of Life","description":"Quality of Life (QoL) was measured with the following questionnaires prior to treatment and after treatment:\n\n* SF-12 short-form health questionnaire (12 items, score: min. 12/max. 47)\n* QoL-AGHDA Assessment of GHD in Adults (25 items: yes/no answers)\n* EQ-5 D Euroquol (5 items, scale per items from 1 (no problems) to 3 (severe problems); 1 Likert scale (0 worst-100 best) to measure health status)\n* BDI Beck Depression Inventory (21 items, score: min. 0/max. 63)\n* PSQI Pittsburgh Sleep Quality Index: (4 items regarding sleep duration, 11 items regarding sleep quality, 1 item regarding sleeping medication, 2 item regarding daytime dysfunction, 1 item regarding sleeping habit; 5 items for third-party assessment)\n* QOLIBRI Quality of Life after Brain Injury (37 items, scale per item from 1 (not at all) to 5 (very much) QoL was measured with difference between mean scores of the respective questionnaires, determined before and after treatment.","timeFrame":"6 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nGroup 1:\n\n1. Age\n2. F/M\n3. Stable phase after TBI, SAH or IS\n4. Stable substitution of other hormonal axes\n5. GH below 6 ng/ml after stimulation with ITT or GH below cut-off in GHRH/arginine test using BMI-adjusted cut-off limits, GHRH/arginine test should be done only in patients denying or with a contraindication for ITT\n6. Written informed consent\n\nGroup 2:\n\n1. Age\n2. M\n3. PSA in normal range\n4. Stable phase after TBI, SAH or IS\n5. Stable substitution of other hormonal axes\n6. Below 3.5 ng/ml testosterone\n7. Written informed consent\n\nGroup 3:\n\n1. Age\n2. F/M\n3. Stable phase after TBI, SAH or IS\n4. GH higher 6 ng/ml after stimulation with ITT or GH below cut-off in GHRH/arginine test using BMI-adjusted cut-off limits, GHRH/arginine test should be done only in patients denying or with a contraindication for ITT\n5. Written informed consent\n\nExclusion Criteria:\n\nGroup 1:\n\n1. Pregnancy/lactation period\n2. Women of childbearing potential not using an adequate method of birth control\n3. Men not willing to use an adequate method of birth control\n4. Previous or concomitant medication with GH\n5. Hypersensitivity to GH\n6. Drug or alcohol abuse\n7. Condition which in opinion of investigator makes patient unsuitable for inclusion\n8. Participation in another clinical trial with investigational new drug\n9. Planned treatment or changes in established treatment with other drug which might significantly influence GH axis or cognitive function\n10. Non-ability to perform testing\n11. Presence of other conditions listed in contraindications or warnings in local SPC of GH\n12. Onset of GH-deficiency before BI\n\nGroup 2:\n\n1. Men not willing to use an adequate method of birth control\n2. Previous or concomitant medication with androgens or anabolic steroids within 12 months\n3. Hypersensitivity to active substances or excipients of Nebido®\n4. Drug or alcohol abuse\n5. Condition which in opinion of investigator makes patient unsuitable for inclusion\n6. Participation in another clinical trial with investigational new drug\n7. Planned treatment or changes in established treatment with other drug which might influence gonadotrophic axis or cognitive function\n8. Severe disturbances in articulation, visual faculty, hearing\n9. Presence of other conditions listed in contraindications or warnings in local SPC of Nebido®\n10. Onset of hormonal deficiency before BI\n11. Suspicion or known history of prostate or breast cancer or other hormone dependent neo plasia as well as history of malignancy within last 5 years\n12. Abnormal finding on DRE\n13. PSA higher 4 ng/ml\n14. History of clinically significant post void residual urine before BI\n15. Suspicion or known history of liver tumor\n16. Blood coagulation irregularities presenting an increased risk of bleeding after i.m injections\n17. Hypercalcemia accompanying malignant tumors\n18. Sleep apnea\n19. Polycythemia\n20. Haematocrit higher than 50 %\n21. Concurrent use of DHEA, anabolic steroids, clomipramine, antiandrogens, estrogen, ACTH, corticosteroids, oxyphenbutazone\n22. Uncontrolled thyroid disorders like diabetes mellitus, epilepsia, migraine, hypertension, coronary heart disease as well as hepatic, renal or cardiac insufficiency\n23. Patients requiring or undergoing fertility treatment\n24. Condition which in opinion of investigator makes patient unsuitable for inclusion\n25. Non-ability to perform cognitive testing\n26. Onset of androgen deficiency before BI.\n\nGroup 3:\n\n1. Previous or concomitant medication with androgens, GH or anabolic steroids within 12 months\n2. Drug or alcohol abuse\n3. Condition which in opinion of investigator makes patient unsuitable for inclusion\n4. Participation in another clinical trial with investigational new drug\n5. Planned treatment or changes in established treatment with other drug which might influence gonadotrophic axis or cognitive function\n6. Severe disturbances in articulation, visual faculty, hearing\n7. Non-ability to perform cognitive testing","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Caroline Sievers, MD","affiliation":"Max Planck Institute","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Max Planck Institute","city":"Muenchen","state":"Bavaria","zip":"80804","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}}]},"referencesModule":{"references":[{"pmid":"30619080","type":"DERIVED","citation":"Leonhardt M, Kopczak A, Schapers B, Limbrock J, Samann PG, Czisch M, von Steinbuechel N, Jordan M, Schneider HJ, Schneider M, Sievers C, Stalla GK. Low Prevalence of Isolated Growth Hormone Deficiency in Patients After Brain Injury: Results From a Phase II Pilot Study. Front Endocrinol (Lausanne). 2018 Dec 17;9:723. doi: 10.3389/fendo.2018.00723. eCollection 2018."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9246","name":"Hemorrhage","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M4897","name":"Brain Injuries","relevance":"LOW"},{"id":"M628","name":"Brain Injuries, Traumatic","relevance":"LOW"},{"id":"M9746","name":"Hypogonadism","relevance":"LOW"},{"id":"T6034","name":"Quality of Life","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC26","name":"Wounds and Injuries"},{"abbrev":"BC19","name":"Gland and Hormone Related Diseases"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000013739","term":"Testosterone"}],"ancestors":[{"id":"D000000728","term":"Androgens"},{"id":"D000006728","term":"Hormones"},{"id":"D000006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M9479","name":"Hormones","relevance":"LOW"},{"id":"M16199","name":"Testosterone","asFound":"10 minutes","relevance":"HIGH"},{"id":"M11441","name":"Methyltestosterone","relevance":"LOW"},{"id":"M223405","name":"Testosterone undecanoate","relevance":"LOW"},{"id":"M223415","name":"Testosterone enanthate","relevance":"LOW"},{"id":"M234967","name":"Testosterone 17 beta-cypionate","relevance":"LOW"},{"id":"M3749","name":"Androgens","relevance":"LOW"},{"id":"M9478","name":"Hormone Antagonists","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"ANeo","name":"Antineoplastic Agents"}]}},"hasResults":false}